45 Non-invasive detection of endometrial cancer by DNA methylation analysis in urine 31. Moreira-Barbosa C, Barros-Silva D, Costa-Pinheiro P, Torres-Ferreira J, Constancio V, Freitas R, et al. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clin Epigenetics. 2018;10(1):132. 32. Larsen LK, Jakobsen JS, Abdul-Al A, Guldberg P. Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration. J Urol. 2018;200(4):749-57. 33. den Helder RV, Wever BM, van Trommel JA, Ket JC, Bleeker MC, Steenbergen RD, et al. DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review. Epigenomics. 2020;12(18):1661-72. 34. Jandaghi P, Hoheisel JD, Riazalhosseini Y. GHSR hypermethylation: a promising pan-cancer marker. Cell Cycle. 2015;14(5):689-90. 35. Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol. 2011;54(2):215-8. 36. Bosschieter J, Bach S, Bijnsdorp IV, Segerink LI, Rurup WF, van Splunter AP, et al. A protocol for urine collection and storage prior to DNA methylation analysis. PLoS One. 2018;13(8):e0200906. 37. Verlaat W, Snijders PJF, Novianti PW, Wilting SM, De Strooper LMA, Trooskens G, et al. Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer. Clin Cancer Res. 2017;23(14):3813-22. 38. Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of obtaining a high yield of cell-free DNA from urine. PLoS One. 2020;15(4):e0231058. 39. Webb M, Manley K, Olivan M, Guldvik I, Palczynska M, Hurst R, et al. Methodology for the at-home collection of urine samples for prostate cancer detection. Biotechniques. 2020;68(2):65-71. 40. Masciullo V, Amadio G, Lo Russo D, Raimondo I, Giordano A, Scambia G. Controversies in the management of endometrial cancer. Obstet Gynecol Int. 2010;2010:638165. 41. Billingsley CC, Kenne KA, Cansino CD, Backes FJ, Cohn DE, O’Malley DM, et al. The Use of Transvaginal Ultrasound in Type II Endometrial Cancer. Int J Gynecol Cancer. 2015;25(5):858-62. 42. Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol. 2006;101(1):120-5. 43. Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12(1):38-48. 44. Park YR, Lee SW, Kim Y, Bae IY, Kim HK, Choe J, et al. Endometrial thickness cut-off value by transvaginal ultrasonography for screening of endometrial pathology in premenopausal and postmenopausal women. Obstet Gynecol Sci. 2019;62(6):445-53. 45. Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):160-7. 46. Aue-Aungkul A, Kleebkaow P, Kietpeerakool C. Incidence and risk factors for insufficient endometrial tissue from endometrial sampling. Int J Womens Health. 2018;10:453-7. 2
RkJQdWJsaXNoZXIy MjY0ODMw